Ambeed.cn

首页 / / / / PD98059

PD98059 {[allProObj[0].p_purity_real_show]}

货号:A282482 同义名: NSC 679828

PD98059是一种非 ATP 竞争性的 MEK 抑制剂,对 MEK1 和 MEK2 的 IC50 分别为 2-7 μM 和 50 μM,抑制 MAPK 激活,且对 TCDD 结合具有抑制作用。PD98059阻止小鼠 ES 细胞的分化,增强人类间充质干细胞的脂肪分化,阻止其成骨分化。

PD98059 化学结构 CAS号:167869-21-8
PD98059 化学结构
CAS号:167869-21-8
PD98059 3D分子结构
CAS号:167869-21-8
PD98059 化学结构 CAS号:167869-21-8
PD98059 3D分子结构 CAS号:167869-21-8
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

PD98059 纯度/质量文件 产品仅供科研

货号:A282482 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
Cell, 2025. Ambeed. [ A122167 ]
Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >
产品名称 MEK MEK1 MEK1/2 MEK2 MEK5 其他靶点 纯度
Honokiol 98%
Mirdametinib ++++

MEK, IC50: 0.33 nM

99%+
Binimetinib +++

MEK, IC50: 12 nM

99%+
BI-847325 ++

MEK1, IC50: 25 nM

+++

MEK2, IC50: 4 nM

99%+
U0126-EtOH +

MEK1, IC50: 0.07 μM

++

MEK2, IC50: 0.06 μM

98%
GDC-0623 ++++

MEK1, IC50: 0.13 nM

99%+
TAK-733 ++++

MEK1, IC50: 3.2 nM

99%+
Trametinib ++++

MEK1, IC50: 0.92 nM

++++

MEK2, IC50: 1.8 nM

99%+
Selumetinib +++

MEK1, Kd: 99 nM

MEK1, IC50: 14 nM

+

MEK2, Kd: 530 nM

99%+
CI-1040 ++

MEK1, IC50: 17 nM

++

MEK2, IC50: 17 nM

99%+
Myricetin 98%
Refametinib ++

MEK1, IC50: 19 nM

++

MEK2, IC50: 47 nM

99%+
Cobimetinib +++

MEK1, IC50: 4.2 nM

99%+
PD98059 +

MEK1, IC50: 2 μM

99%+
SL327 +

MEK1, IC50: 0.18 μM

+

MEK2, IC50: 0.22 μM

AP-1 98+%
PD318088 99%
AZD8330 +++

MEK1/2, IC50: 7 nM

99%+
Pimasertib 98%
(E/Z)-BIX02189 ++++

MEK5, IC50: 1.5 nM

99%+
(E/Z)-BIX02188 +++

MEK5, IC50: 4.3 nM

99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

PD98059 生物活性

靶点
  • MEK1

    MEK1, IC50:2 μM

描述 MEKs, which are members of the MAPKK family, can activate both ERK1 and ERK2 by catalyzing the phosphorylation on T202/Y204. Also MEK itself can be phosphorylated and activated through Ras when the upstream signaling is activated by extracellular stimuli, including growth factors, hormones etc.. PD98059 is MEK1/2-specific inhibitor with IC50=~10uM (measured by phosphorylation level of MAPK-KA catalyzed by GST-MEK1) with no effect on ERK. Pre-incubation of PD98059 can inhibit PDGF-stimulated tyrosine phosphorylation of MAPK while preventing thymidine incorporation with an IC50 of 7 uM in 3T3 cells. PD98059 did not show significant inhibitory activity on Raf kinase, cAMP-dependent kinase, protein kinase C, v-Src, EGF receptor kinase, insulin receptor kinase, PDGFreceptor kinase, and PI3Ks, which shows the high selectivity of it [1]. PD98059 is the first generation small molecule inhibitors of MEK1/2. PD98059 does not interfere with Raf access to MEK1/2 for it did not affect serum-induced MEK1/2 phosphorylation [2].
作用机制 PD 098059 does not complete for ATP binding or MAPK binding to MEK and most likely inhibits through an allosteric mechanism.[1]

PD98059 细胞实验

Cell Line
Concentration Treated Time Description References
Human intrahepatic biliary epithelial cells (HIBEpiCs) 10 μM 24 h Pretreatment with PD98059 reduced apelin-induced ERK phosphorylation and cholangiocyte proliferation Hepatology. 2021 Jun;73(6):2411-2428.
Y79 cells 0.1 µM, 0.2 µM, 0.39 µM, 0.78 µM, 1.56 µM, 3.12 µM, 6.25 µM, 12.5 µM 22 h To evaluate the effects of PD98059 on the metabolic activity and cytotoxicity of Y79 cells. PD98059 significantly inhibited cellular metabolic activity at a concentration of 3.12 µM or higher, but did not significantly increase cytotoxicity. Theranostics. 2022 Sep 11;12(15):6705-6722.
huPMCs cells 0.1 µM, 0.2 µM, 0.39 µM, 0.78 µM, 1.56 µM, 3.12 µM, 6.25 µM, 12.5 µM 22 h To evaluate the effects of PD98059 on the metabolic activity and cytotoxicity of huPMCs cells. PD98059 did not significantly inhibit cellular metabolic activity at concentrations up to 12.5 µM, nor did it significantly increase cytotoxicity. Theranostics. 2022 Sep 11;12(15):6705-6722.
MIO-M1 cells 0.1 µM, 0.2 µM, 0.39 µM, 0.78 µM, 1.56 µM, 3.12 µM, 6.25 µM, 12.5 µM 22 h To evaluate the effects of PD98059 on the metabolic activity and cytotoxicity of MIO-M1 cells. PD98059 significantly inhibited cellular metabolic activity at a concentration of 1.56 µM or higher, but did not significantly increase cytotoxicity. Theranostics. 2022 Sep 11;12(15):6705-6722.
U87 cells 5 μM 12 h To investigate the effect of PD98059 on RRM2 overexpression in U87 cells, the results showed that PD98059 inhibited the phosphorylation of ERK1/2 and blocked the upregulation of cyclin B1, cyclin D1, and N-cadherin expression induced by RRM2 overexpression. Int J Biol Sci. 2019 Jan 1;15(3):533-543.
Human adipose-derived stem cells (hASCs) 5 μM 48 h To investigate the effect of PD98059 on FGF-2-mediated proliferation of hASCs, results showed that PD98059 significantly inhibited FGF-2-mediated cell proliferation. Stem Cell Res Ther. 2019 Nov 27;10(1):350.
human adipose tissue-derived stem cells (hADSCs) 40 μM 30 min PD98059 abolished the ERK1/2 phosphorylation and proliferation induced by silica NPs Int J Nanomedicine. 2015 Mar 24;10:2261-72.
MIA-PaCa-2 cells 25 µM PD98059 completely blocked KIF15-mediated pancreatic cancer cell proliferation Br J Cancer. 2017 Jul 11;117(2):245-255.
PANC-1 cells 25 µM PD98059 completely blocked KIF15-mediated pancreatic cancer cell proliferation Br J Cancer. 2017 Jul 11;117(2):245-255.

PD98059 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Mice Photo-oxidative damage model Intravitreal injection 100 µM Single injection, lasting 4 days To evaluate the protective effects of PD98059 on the retina of photo-oxidative damage mice. PD98059 significantly inhibited the phosphorylation of pERK1/2, reduced the expression of the gliotic marker GFAP in Müller cells, and increased the levels of the neuroprotective factor IRBP in photoreceptors. PD98059 also reduced photoreceptor apoptosis in photo-oxidative damage mice and assessed its protective effects on retinal function through OCT and ERG. Theranostics. 2022 Sep 11;12(15):6705-6722.
Balb/c nude mice Orthotopic pancreatic cancer transplantation model Subcutaneous injection 10 mg/kg Once daily for 9 weeks PD98059 blocked KIF15-mediated pancreatic cancer proliferation and prolonged the survival time of mice Br J Cancer. 2017 Jul 11;117(2):245-255.

PD98059 动物研究

Dose Mice: 10 mg/kg[3]
Administration i.v.

PD98059 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.74mL

0.75mL

0.37mL

18.71mL

3.74mL

1.87mL

37.41mL

7.48mL

3.74mL

PD98059 技术信息

CAS号167869-21-8
分子式C16H13NO3
分子量 267.28
SMILES Code O=C1C=C(C2=CC=CC(OC)=C2N)OC3=C1C=CC=C3
MDL No. MFCD00671789
别名 NSC 679828
运输蓝冰
InChI Key QFWCYNPOPKQOKV-UHFFFAOYSA-N
Pubchem ID 4713
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry, store in freezer, under -20°C

溶解方案

DMSO: 35 mg/mL(130.95 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案 一
配制的工作液建议现用现配,短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案 一
AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。